Processes used in England by health technology appraisal body NICE to evaluate rare disease treatments are not fit for purpose and should be reformed, claims a new report from the market access consulting firm MAP Biopharma.
UK NICE Processes Not Fit For Orphan Drugs, Says New Report
UK health technology appraisal body NICE says it will carefully review a new report that has found its processes block access to orphan drugs.
